Three-dimensional genetically engineered cell and tissue culture system

• US 5,785,964 A
• Filed: 04/06/1995
• Issued: 07/28/1998
• Est. Priority Date: 04/18/1986
• Status: Expired due to Term

• Current Assignee: Smith & Nephew Wound Management (Smith & Nephew PLC)
• Original Assignee: Advanced Tissue Sciences, Inc.
• Inventors: Naughton, Gail K., Naughton, Brian A.
• Primary Examiner(s): Low, Christopher S. F.
• Application Number:
  US08/418,238
• Time in Patent Office: 1,209 Days
• Field of Search: 424/93.21, 424/93.1, 424/93.2, 424/93.3, 424/422, 424/423, 424/426, 435/240.2, 435/240.243, 435/320.1, 435/172.3, 435/1.1, 435/240.23, 435/240.241, 435/325, 435/326, 435/347-373, 935/66, 935/70
• US Class Current: 424/93.21
• CPC Class Codes: A61B 2010/0258 Marrow samples
• CPC Class Codes: A61B 90/00 Instruments, implements or accessories specially adapted for surgery or diagnosis and not covered by any of the groups A61B1/00 - A61B50/00, e.g. for luxation treatment or for protecting wound edges protective face masks A41D13/11; surgeon's or patient's gowns or dresses A41D13/12; devices for carrying-off, for treatment of, or for carrying-over, body liquids A61M1/00
• CPC Class Codes: A61K 2035/124 the cells being hematopoietic, bone marrow derived or blood cells
• CPC Class Codes: A61K 35/12 Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells vaccines or medicinal preparations containing antigens or antibodies A61K39/00
• CPC Class Codes: A61K 35/28 Bone marrow; Haematopoietic stem cells; Mesenchymal stem cells of any origin, e.g. adipose-derived stem cells
• CPC Class Codes: A61L 27/3604 characterised by the human or animal origin of the biological material, e.g. hair, fascia, fish scales, silk, shellac, pericardium, pleura, renal tissue, amniotic membrane, parenchymal tissue, fetal tissue, muscle tissue, fat tissue, enamel
• CPC Class Codes: A61L 27/3886 comprising two or more cell types
• CPC Class Codes: A61L 27/60 Materials for use in artificial skin
• CPC Class Codes: C12N 2500/34 Sugars
• CPC Class Codes: C12N 2501/11 Epidermal growth factor [EGF]
• CPC Class Codes: C12N 2501/33 Insulin together with transferrin C12N2500/25; Insulin-like growth factors C12N2501/105
• CPC Class Codes: C12N 2501/335 Glucagon; Glucagon-like peptide [GLP]; Exendin
• CPC Class Codes: C12N 2501/39 Steroid hormones
• CPC Class Codes: C12N 2502/091 melanocytes
• CPC Class Codes: C12N 2502/094 keratinocytes
• CPC Class Codes: C12N 2502/1323 Adult fibroblasts
• CPC Class Codes: C12N 2503/04 Screening or testing on artificial tissues
• CPC Class Codes: C12N 2510/00 Genetically modified cells
• CPC Class Codes: C12N 2533/30 Synthetic polymers thermoreactive polymers, e.g. PNIPAm, C12N2539/10
• CPC Class Codes: C12N 2533/40 Polyhydroxyacids, e.g. polymers of glycolic or lactic acid (PGA, PLA, PLGA); Bioresorbable polymers
• CPC Class Codes: C12N 2533/70 : Polysaccharides
• CPC Class Codes: C12N 5/0698 : Skin equivalents
• CPC Class Codes: Y10S 623/915 : Method or apparatus for preparing biological material

Abstract

The present invention relates to a three-dimensional cell culture system which can be used to culture a variety of different cells and tissues in vitro for prolonged periods of time. In accordance with the invention, cells derived from a desired tissue are inoculated and grown on a pre-established stromal support matrix. The stromal support matrix comprises stromal cells, such as fibroblasts actively growing on a three-dimensional matrix. Stromal cells may also include other cells found in loose connective tissue such as endothelial cells, macrophages/monocytes, adipocytes, pericytes, reticular cells found in bone marrow stroma, etc. The stromal matrix provides the support, growth factors, and regulatory factors necessary to sustain long-term active proliferation of cells in culture. When grown in this three-dimensional system, the proliferating cells mature and segregate properly to form components of adult tissues analogous to counterparts found in vivo.

Claims

1. A genetically engineered living stromal tissue prepared in vitro, comprising stromal cells transfected with an exogenous gene under the control of an expression element so that the exogenous gene product is expressed, in which both the transfected stromal cells and connective tissue proteins naturally secreted by the transfected stromal cells are attached to and substantially envelope a framework composed of a biocompatible, nonliving material thereby forming a three-dimensional structure having interstitial spaces bridged by the transfected stromal cells.

2. The genetically engineered living stromal tissue of claim 1 in which the transfected stromal cells are fibroblasts.

3. The genetically engineered living stromal tissue of claim 1 in which the transfected stromal cells are a combination of fibroblasts and endothelial cells, pericytes, macrophages, monocytes, leukocytes, plasma cells, mast cells or adipocytes.

4. The genetically engineered living stromal tissue of claim 1 in which the framework is composed of a biodegradable material.

5. The genetically engineered living stromal tissue of claim 4 in which the biodegradable material is cotton, polyglycolic acid, cat gut sutures, cellulose, gelatin, or dextran.

6. The genetically engineered living stromal tissue of claim 1 in which the framework is composed of a non-biodegradable material.

7. The genetically engineered living stromal tissue of claim 6 in which the non-biodegradable material is a polyamide, a polyester, a polystyrene, a polypropylene, a polyacrylate, a polyvinyl, a polycarbonate, a polytetrafluorethylene, or a nitrocellulose compound.

8. The genetically engineered living stromal tissue of claim 4, 5, 6, or 7 in which the framework is pre-coated with collagen.

9. The genetically engineered living stromal tissue of claim 1, 2, 3, 4, 5, 6 or 7 in which the framework is a mesh.

10. The genetically engineered living stromal tissue of claim 7 in which the framework is a mesh.

11. A three-dimensional cell culture of genetically engineered dermis prepared in vitro, comprising stromal cells transfected with an exogenous gene under the control of an expression element so that the exogenous gene product is expressed, in which both the transfected stromal cells and connective tissue proteins naturally secreted by the transfected stromal cells are attached to and substantially envelope a framework composed of a biocompatible, non-living material thereby forming a three-dimensional structure having interstitial spaces bridged by the transfected stromal cells.

12. A three-dimensional cell culture comprising parenchymal cells cultured on a genetically engineered living stromal tissue prepared in vitro, comprising stromal cells transfected with an exogenous gene under the control of an expression element so that the exogenous gene product is expressed, in which both the transfected stromal cells and connective tissue proteins naturally secreted by the transfected stromal cells are attached to and substantially envelope a framework composed of a biocompatible, non-living material thereby forming a three-dimensional structure having interstitial spaces bridged by the transfected stromal cells.

13. The three-dimensional cell culture of claim 12 in which the parenchymal cells are hematopoietic cells.

14. The three-dimensional cell culture of claim 12 in which the parenchymal cells are melanocytes and keratinocytes.

15. The three-dimensional cell culture of claim 12 in which the parenchymal cells are liver parenchymal cells.

16. The three-dimensional cell culture of claim 12 in which the parenchymal cells are pancreatic acinar cells.

17. The three-dimensional cell culture of claim 12 in which the parenchymal cells are kidney parenchymal cells.

18. The three-dimensional cell culture of claim 12 in which the parenchymal cells are mucosal epithelium cells.

19. The three-dimensional cell culture of claim 12 in which the parenchymal cells are neurons and astrocytes.

20. The three-dimensional cell culture of claims 12, 13, 14, 15, 16, 17, 18 or 19 in which the parenchymal cells are transfected parenchymal cells containing an exogenous gene under the control of an expression element.

21. A three-dimensional genetically engineered cell culture comprising transfected parenchymal sells cultured on a living stromal tissue prepared in vitro, in which both:

(i) the transfected parenchymal cells contain an exogenous gene under the control of an expression element so that the exogenous gene product is expressed; and

(ii) the living stromal tissue comprises stromal cells and connective tissue proteins naturally secreted by the stromal cells attached to and substantially enveloping a framework composed of a biocompatible, non-living material thereby forming a three-dimensional structure having interstitial spaces bridged by the stromal cells.

22. The three-dimensional genetically engineered cell culture of claim 21 in which the stromal cells are fibroblasts.

23. The three-dimensional genetically engineered cell culture of claim 21 in which the stromal cells are a combination of fibroblasts and endothelial cells, pericytes, macrophages, monocytes, leukocytes, plasma cells, mast cells or adipocytes.

24. The three-dimensional genetically engineered cell culture of claim 21 in which the framework is composed of a biodegradable material.

25. The three-dimensional genetically engineered cell culture of claim 24 in which the biodegradable material is cotton, polyglycolic acid, cat gut sutures, cellulose, gelatin, or dextran.

26. The three-dimensional genetically engineered cell culture of claim 21 in which the framework is composed of a non-biodegradable material.

27. The three-dimensional genetically engineered cell culture of claim 26 in which the non-biodegradable material is a polyamide, a polyester, a polystyrene, a polypropylene, a polyacrylate, a polyvinyl, a polycarbonate, a polytetrafluorethylene, or a nitrocellulose compound.

28. The three-dimensional genetically engineered cell culture of claim 24, 28, 29 or 30 in which the framework is pre-coated with collagen.

29. The three-dimensional genetically engineered cell culture of claim 24, 25, 26, 27, 28, 29, or 30 in which the framework is a mesh.

30. The three-dimensional genetically engineered cell culture of claim 28 in which the framework is a mesh.

31. The three-dimensional genetically engineered culture of claim 24 in which the transfected parenchymal cells are hematopoietic cells.

32. The three-dimensional genetically engineered culture of claim 24 in which the transfected parenchymal cells are melanocytes or keratinocytes.

33. The three-dimensional genetically engineered culture of claim 24 in which the transfected parenchymal cells are liver parenchymal cells.

34. The three-dimensional genetically engineered culture of claim 21 in which the transfected parenchymal cells are pancreatic acinar cells.

35. The three-dimensional genetically engineered culture of claim 21 in which the transfected parenchymal cells are kidney parenchymal cells.

36. The three-dimensional genetically engineered culture of claim 21 in which the transfected parenchymal cells are mucosal epithelium cells.

37. A three-dimensional genetically engineered culture system comprising neuron cells and transfected astrocytes cultured on a living stromal tissue prepared in vitro, in which both:

(i) the transfected astrocytes contain an exogenous gene under the control of an expression element so that the exogenous gene product is expressed; and

(ii) the living stromal tissue comprises confluent small blood vessel endothelial cells attached to and substantially enveloping a framework composed of a biocompatible, non-living material thereby forming a three-dimensional structure having interstitial spaces bridged by the endothelial cells.

38. A three-dimensional genetically engineered culture system comprising transfected neuron cells and astrocytes cultured on a living stromal tissue prepared in vitro, in which both:

(i) the transfected neuron cells contain an exogenous gene under the control of an expression element so that the exogenous gene product is expressed; and

(ii) the living stromal tissue comprises confluent small blood vessel endothelial cells attached to and substantially enveloping a framework composed of a biocompatible, non-living material thereby forming a three-dimensional structure having interstitial spaces bridged by the endothelial cells.

39. A method for implantation in vivo of a genetically engineered living stromal tissue prepared in vitro, comprising implanting the genetically engineered living stromal tissue comprising stromal cells transfected with an exogenous gene under the control of an expression element so that the exogenous gene product is expressed, in which both the transfected stromal cells and connective tissue proteins naturally secreted by the transfected stromal cells are attached to and substantially envelope a framework composed of a biocompatible, non-living material thereby forming a three-dimensional structure having interstitial spaces bridged by the transfected stromal cells, so that a tissue equivalent is formed in vivo.

40. The method of implantation according to claim 39 in which the transfected stromal cells are fibroblasts.

41. The method of implantation according to claim 39 in which the transfected stromal cells are a combination of fibroblasts and endothelial cells, pericytes, macrophages, monocytes, leukocytes, plasma cells, mast cells or adipocytes.

42. The method of implantation according to claim 39 in which the framework is composed of a biodegradable material.

43. The method of implantation according to claim 39 in which the biodegradable material is cotton, polyglycolic acid, cat gut sutures, cellulose, gelatin, or dextran.

44. The method of implantation according to claim 39 in which the framework is composed of a non-biodegradable material.

45. The method of implantation according to claim 44 in which the non-biodegradable material is a polyamide, a polyester, a polystyrene, a polypropylene, a polyacrylate, a polyvinyl, a polycarbonate, a polytetrafluorethylene, or a nitrocellulose compound.

46. The method of implantation according to claim 42, 43, 44 or 45 in which the framework is pre-coated with collagen.

47. The method of implantation according to claim 39, 40, 41, 42, 43 or 44 in which the framework is a mesh.

48. The method of implantation according to claim 46 in which the framework is a mesh.

49. The method of implantation according to claim 39 in which the tissue equivalent is dermis.

50. A method of implanting in vivo a genetically engineered three-dimensional cell culture prepared in vitro, comprising implanting a culture of parenchymal cells inoculated onto a genetically engineered living stromal tissue, comprising stromal cells transfected with an exogenous gene under the control of an expression element so that the exogenous gene product is expressed, in which both the transfected stromal cells and connective tissue proteins naturally secreted by the transfected stromal cells are attached to and substantially envelope a framework composed of a biocompatible, non-living material thereby forming a three-dimensional structure having interstitial spaces bridged by the transfected stromal cells, so that a tissue equivalent is formed in vivo.

51. The method of implantation according to claim 50 in which the transfected stromal cells are fibroblasts.

52. The method of implantation according to claim 50 in which the transfected stromal cells are a combination of fibroblasts and endothelial cells, pericytes, macrophages, monocytes, leukocytes, plasma cells, mast cells or adipocytes.

53. The method of implantation according to claim 50 in which the framework is composed of a biodegradable material.

54. The method of implantation according to claim 53 in which the biodegradable material is cotton, polyglycolic acid, cat gut sutures, cellulose, gelatin, or dextran.

55. The method of implantation according to claim 50 in which the framework is composed of a non-biodegradable material.

56. The method of implantation according to claim 55 in which the non-biodegradable material is a polyamide, a polyester, a polystyrene, a polypropylene, a polyacrylate, a polyvinyl, a polycarbonate, a polytetrafluorethylene, or a nitrocellulose compound.

57. The method of implantation according to claim 53, 54, 55 or 56 in which the framework is pre-coated with collagen.

58. The method of implantation according to claim 50, 51, 52, 53, 54, 55 or 56 in which the framework is a mesh.

59. The method of implantation according to claim 57 in which the framework is a mesh.

60. The method of implantation of claim 50 in which the parenchymal cells are melanocytes and keratinocytes.

61. The method of implantation of claim 50 in which the parenchymal cells are liver parenchymal cells.

62. The method of implantation of claim 50 in which the parenchymal cells are pancreatic acinar cells.

63. The method of implantation of claim 50 in which the parenchymal cells are kidney parenchymal cells.

64. The method of implantation of claim 50 in which the parenchymal cells are mucosal epithelial cells.

65. The method of implantation of claim 50 in which the parenchymal cells are neurons and astrocytes.

67. The method of implantation according to claims 50, 60, 61, 62, 63, 64, 65 or 66 in which the parenchymal cells are transfected parenchymal cells containing a exogenous gene under the control of an expression element.

66. A method for transplantation or implantation of bone marrow cells in vivo, comprising implanting in vivo the hematopoietic cells cultured on a genetically engineered living stromal tissue prepared in vitro, in which both:

(a) the genetically engineered living stromal tissue comprises transfected stromal cells which contain an exogenous gene under the control of an expression element so that the exogenous gene product is expressed, in which the transfected stromal cells and connective tissue proteins naturally secreted by the transfected stromal cells are attached to and substantially envelope a framework composed of a biocompatible, non-living material thereby forming a three-dimensional structure having interstitial spaces bridged by the stromal cells so that the hematopoietic cells proliferate in the culture.

68. A method for transplantation or implantation of genetically engineered cells in vivo, comprising implanting in vivo transfected parenchymal cells cultured on a living stromal tissue prepared in vitro in which both:

(a) the transfected parenchymal cells contain an exogenous gene under the control of an expression element so that the exogenous gene product is expressed; and

(b) the living stromal tissue comprises stromal cells and connective tissue proteins naturally secreted by the stromal cells attached to and substantially enveloping a framework composed of a biocompatible, non-living material thereby forming a three-dimensional structure having interstitial spaces bridged by the stromal cells so that a tissue equivalent is formed.

69. The method according to claim 68 in which the stromal cells are fibroblasts.

70. The method according to claim 68 in which the stromal cells are a combination of fibroblasts and endothelial cells, pericytes, macrophages, monocytes, leukocytes, plasma cells, mast cells or adipocytes.

71. The method according to claim 68 in which the framework is composed of a biodegradable material.

72. The method according to claim 68 in which the biodegradable material is cotton, polyglycolic acid, cat gut sutures, cellulose, gelatin, or dextran.

73. The method according to claim 68 in which the framework is composed of a non-biodegradable material.

74. The method according to claim 73 in which the non-biodegradable material is a polyamide, a polyester, a polystyrene, a polypropylene, a polyacrylate, a polyvinyl, a polycarbonate, a polytetrafluorethylene, or a nitrocellulose compound.

75. The method according to claim 71, 72, 73 or 74 in which the framework is pre-coated with collagen.

76. The method according to claim 68, 69, 70, 71, 72, 73 or 74 in which the framework is a mesh.

77. The method according to claim 75 in which the framework is a mesh.

78. The method for transplantation or implantation of genetically engineered bone marrow cells in vivo, comprising implanting in vivo the transfected hematopoietic cells cultured on a living stromal tissue prepared in vitro, in which both:

(a) the transfected hematopoietic cells contain an exogenous gene under the control of an expression element so that the exogenous gene product is expressed; and

(b) the living stromal tissue, comprises stromal cells and connective tissue proteins naturally secreted by the stromal cells attached to and substantially enveloping a framework composed of a biocompatible, non-living material thereby forming a three-dimensional structure having interstitial spaces bridged by the stromal cells.

79. A method for transplantation or implantation of genetically engineered skin cells in vivo comprising implanting in vivo the transfected melanocyte or keratinocyte cells cultured on a living stromal tissue prepared in vitro in which both:

(a) the transfected melanocyte or keratinocyte cells contain an exogenous gene under the control of an expression element so that the exogenous gene product is expressed; and

(b) the living stromal tissue comprises stromal cells and connective tissue proteins naturally secreted by the stromal cells attached to and substantially enveloping a framework composed of a biocompatible, non-living material thereby forming a three-dimensional structure having interstitial spaces bridged by the stromal cells so that a tissue equivalent is formed.

80. A method for transplantation or implantation of genetically engineered liver cells in vivo comprising implanting in vivo the transfected liver parenchymal cells cultured on a living stromal tissue prepared in vitro in which both:

(a) the transfected liver parenchymal cells contain an exogenous gene under the control of an expression element so that the exogenous gene product is expressed; and

(b) the living stromal tissue comprises stromal cells and connective tissue proteins naturally secreted by the stromal cells attached to and substantially enveloping a framework composed of a biocompatible, non-living material thereby forming a three-dimensional structure having interstitial spaces bridged by the stromal cells so that a tissue equivalent is formed.

81. A method for transplantation or implantation of genetically engineered pancreatic cells in vivo comprising implanting in vivo the transfected pancreatic acinar cells cultured on a living stromal tissue prepared in vitro in which both:

(a) the transfected pancreatic acinar cells contain an exogenous gene under the control of an expression element so that the exogenous gene product is expressed; and

(b) the living stromal tissue comprises stromal cells and connective tissue proteins naturally secreted by the stromal cells attached to and substantially enveloping a framework composed of a biocompatible, non-living material thereby forming a three-dimensional structure having interstitial spaces bridged by the stromal cells so that a tissue equivalent is formed.

82. A method for transplantation or implantation of genetically engineered kidney cells in vivo comprising transplanting in vivo the transfected kidney parenchymal cells cultured on a living stromal tissue prepared in vitro in which both:

(a) the transfected kidney parenchymal cells contain an exogenous gene under the control of an expression element so that the exogenous gene product is expressed; and

(b) the living stromal tissue comprises stromal cells and connective tissue proteins naturally secreted by the stromal cells attached to and substantially enveloping a framework composed of a biocompatible, non-living material thereby forming a three-dimensional structure having interstitial spaces bridged by the stromal cells so that a tissue equivalent is formed.

83. A method for transplantation or implantation of genetically engineered mucosal epithelium cells in vivo comprising implanting in vivo the transfected mucosal epithelium cells cultured on a living stromal tissue prepared in vitro in which both:

(a) the transfected mucosal epithelium cells contain an exogenous gene under the control of an expression element so that the exogenous gene product is expressed; and

(b) the living stromal tissue comprises stromal cells and connective tissue proteins naturally secreted by the stromal cells attached to and substantially enveloping a framework composed of a biocompatible, non-living material thereby forming a three-dimensional structure having interstitial spaces bridged by the stromal cells so that a tissue equivalent is formed.

84. A method for transplantation or implantation of a genetically engineered blood-brain barrier cell culture in vivo comprising transplanting in vivo the neuron cells and transfected astrocytes cultured on a living stromal tissue prepared in vitro, in which both:

(a) the transfected astrocytes contain an exogenous gene under the control of an expression element so that the exogenous gene product is expressed; and

(b) the living stromal tissue comprises confluent small blood vessel endothelial cells attached to and substantially enveloping a framework composed of a biocompatible, non-living material thereby forming a three-dimensional structure having interstitial spaces bridged by the endothelial cells so that a tissue equivalent is formed.

85. A method for transplantation or implantation of a three-dimensional genetically engineered blood-brain barrier cell culture in vivo comprising implanting in vivo the transfected neuron cells and astrocytes cultured on a living stromal tissue prepared in vitro, in which both:

(a) the transfected neuron cells contain an exogenous gene under the control of an expression element so that the exogenous gene product is expressed; and

(b) the living stromal tissue comprises confluent small blood vessel endothelial cells attached to and substantially enveloping a framework composed of a biocompatible, non-living material thereby forming a three-dimensional structure having interstitial spaces bridged by the endothelial cells so that a tissue equivalent is formed.